Lilly's schizophrenia product misses Phase IIb endpoints

Eli Lilly and Co. (NYSE:LLY) reported data from a pivotal Phase IIb trial showing that oral pomaglumetad methionil as monotherapy for schizophrenia missed the co-primary endpoints of improving Positive and Negative Syndrome Scale (PANSS) total score from baseline vs. placebo in the overall population and in an undisclosed predefined genetic subgroup of schizophrenia patients. Eli Lilly said that the active control risperidone met the co-primary endpoints vs. placebo. Pomaglumetad methionil is a prodrug of LY404039, a metabotropic glutamate receptor subtype 2/3 ( mGluR2/3) agonist. ...